Alpha 2.0
Login Register
» Authors » Jukka Westerbacka

Jukka Westerbacka

Explore the profile of Jukka Westerbacka including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 57
Citations 2458
Followers 0
Related Specialties
Endocrinology
Cardiology & Vascular Diseases
Physiology
Top 10 Co-Authors
Hannele Yki-Jarvinen
Marja-Riitta Taskinen
Satu Vehkavaara
Anna Kotronen
Robert Bergholm
Anna-Maija Hakkinen
Zsolt Bosnyak
Nina Lundbom
Rachel M Fisher
Antti Hakkarainen
Published In
Diabetes Obes Metab
J Clin Endocrinol Metab
Arterioscler Thromb Vasc Biol
Diabetes
Diabetes Care
Affiliations
Soon will be listed here.
Recent Articles
1.
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial
Battelino T, Danne T, Edelman S, Choudhary P, Renard E, Westerbacka J, et al.
Diabetes Obes Metab . 2022 Oct; 25(2):545-555. PMID: 36263928
Aim: To use continuous glucose monitoring (CGM)-based time-in-range (TIR) as a primary efficacy endpoint to compare the second-generation basal insulin (BI) analogues insulin glargine 300 U/ml (Gla-300) and insulin degludec...
2.
Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study
Bailey T, Gill J, Jones S M, Shenoy L, Nicholls C, Westerbacka J
Diabetes Obes Metab . 2022 May; 24(8):1617-1622. PMID: 35491520
Aims: To provide real-world data on the addition of basal insulin (BI) in people with type 2 diabetes mellitus (PWD2) suboptimally controlled with glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. However,...
3.
A review of reusable insulin pens and features of TouStar-a new reusable pen with a dedicated cartridge
Veasey R, Ruf C, Bogatirsky D, Westerbacka J, Friedrichs A, Abdel-Tawab M, et al.
Diabetol Metab Syndr . 2021 Dec; 13(1):147. PMID: 34924015
Background: Since the introduction of the first reusable insulin pen, the advancement in the design of these pens is still ongoing to develop a safe, more efficacious, less painful, and...
4.
Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study
Sullivan S, Freemantle N, Gupta R, Wu J, Nicholls C, Westerbacka J, et al.
Endocrinol Diabetes Metab . 2021 Nov; 5(1):e00306. PMID: 34807513
Aims: To compare 12-month clinical effectiveness of insulin glargine 300 units/mL (Gla-300) versus first-generation basal insulin analogues (BIAs) (insulin glargine 100 units/mL [Gla-100] or insulin detemir [IDet]) in patients with...
5.
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
Bolli G, Cheng A, Charbonnel B, Aroda V, Westerbacka J, Bosnyak Z, et al.
Diabetes Obes Metab . 2021 Mar; 23(7):1588-1593. PMID: 33687748
Aim: To evaluate the efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus insulin degludec 100 U/mL (IDeg-100) in predefined (</≥65 years) and post hoc (</≥70 years) age groups...
6.
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?
Mauricio D, Westerbacka J, Nicholls C, Wu J, Gupta R, Eliasson B
Diabetes Obes Metab . 2020 Nov; 23(3):838-843. PMID: 33236461
Randomized controlled trial (RCT) populations often do not reflect those typically seen in clinical practice. This retrospective, observational cohort study analysed the real-world data of people with type 2 diabetes...
7.
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial
Haluzik M, Cheng A, Muller-Wieland D, Westerbacka J, Bosnyak Z, Lauand F, et al.
Diabetes Obes Metab . 2020 Apr; 22(8):1369-1377. PMID: 32243043
Aims: Chronic kidney disease (CKD) challenges diabetes management and is associated with increased cardiovascular morbidity and mortality. We examined whether clinical outcomes with insulin glargine 300 U/mL (Gla-300) and insulin...
8.
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus
Freemantle N, Mauricio D, Giaccari A, Bailey T, Roussel R, Franco D, et al.
Curr Med Res Opin . 2019 Dec; 36(4):571-581. PMID: 31865758
To compare real-world outcomes with newer (insulin glargine 300 U/mL; Gla-300) versus standard of care (SoC) basal insulins (BIs) in the REACH (insulin-naïve; NCT02967224) and REGAIN (basal insulin-treated; NCT02967211) studies...
9.
Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study
Cheng A, Harris S, Giorgino F, Seufert J, Ritzel R, Khunti K, et al.
Diabetes Obes Metab . 2019 Oct; 22(3):346-354. PMID: 31646724
Aim: To further investigate glycaemic control and hypoglycaemia in BRIGHT, focusing on the titration period. Materials And Methods: BRIGHT was a multicentre, open-label, randomized, active-controlled, two-arm, parallel-group, 24-week study in...
10.
Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3)
Bailey T, Wu J, Zhou F, Gupta R, Menon A, Berhanu P, et al.
Diabetes Obes Metab . 2019 Jul; 21(11):2384-2393. PMID: 31264346
Aim: To compare the second-generation basal insulin glargine 300 units/mL (Gla-300) and first-generation basal insulins on glycaemic control and hypoglycaemia risk in older adults with type 2 diabetes (T2D). Materials...